Biogen | BIIB - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Acadia Pharmaceuticals USD 0 4.12M 2024-09
ALKERMES USD 20.89M 8.62M 2026-03
Amgen USD 657M 4M 2026-03
Bayer EUR 675M 87M 2025-12
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Bristol-Myers Squibb USD 411M 21M 2026-03
Eli Lilly USD 114.7M 134.3M 2025-09
Esperion Therapeutics USD 22.64M 585K 2025-12
Gilead Sciences USD 240M 15M 2026-03
Incyte USD 569K 13K 2026-03
Merck USD 479M 67M 2026-03
Moderna USD 11.49B 36B 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 343M 39M 2026-03
Pfizer USD 671M 40M 2026-03
PTC Therapeutics USD 2.87B 2.82B 2026-03
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR 178M 203M 2026-03
Sanofi EUR -25M 99.78M 2025-12
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
Teva Pharmaceutical Industries USD 216M 4M 2026-03
Ultragenyx Pharmaceutical USD 21M 2M 2026-03
United Therapeutics USD 3.1M 100K 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12